The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies

This chapter contains sections titled: Introduction Questions Literature‐search strategy and inclusions Do patients with hematologic malignancies benefit from the addition of EPO in the treatment of chemotherapy‐induced anemia? What are the benefits and harms associated with the use of CSFs as primary prophylaxis of chemotherapy‐induced febrile neutropenia? References Introduction Questions Literature‐search strategy and inclusions Do patients with hematologic malignancies benefit from the addition of EPO in the treatment of chemotherapy‐induced anemia? What are the benefits and harms associated with the use of CSFs as primary prophylaxis of chemotherapy‐induced febrile neutropenia? References